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While the nasal mucosa is a potentially useful site for human immunization, toxin-
based nasal adjuvants are generally unsafe and less effective in humans. Safe mu-
cosal adjuvants that activate protective immunity via mucosal administration are highly
dependent on barrier antigen sampling by epithelial and DCs. Here, we demonstrate
that protein antigens formulated in unique oil-in-water nanoemulsions (NEs) result in
distinctive transcellular antigen uptake in ciliated nasal epithelial cells, leading to de-
livery into nasal associated lymphoid tissue. NE formulation also enhances MHC class II
expression in epithelial cells and DC activation/trafficking to regional lymphoid tissues in
mice. These materials appear to induce local epithelial cell apoptosis and heterogeneous
cytokine production by mucosal epithelial cells and mixed nasal tissues, including G-CSF,
GM-CSF, IL-1a, IL-1b, IL-5, IL-6, IL-12, IP-10, KC, MIP-1a, TGF-β, and TSLP. This is the first
observation of a nasal adjuvant that activates calreticulin-associated apoptosis of ciliated
nasal epithelial cells to generate broad cytokine/chemokine responses in mucosal tissue.
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Introduction
The respiratory mucosa is the main port of entry for many im-
portant human pathogens including influenza, adeno, corona,
rhino, and respiratory syncytial viruses, Mycobacteria tuberculo-
sis, Streptococcus pneumoniae, and others. The nasal cavity is the
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first anatomical interface between these airborne microorganisms
and the airway mucosa [1]. Recent evidence points to the concept
that early events in nasal pathogen invasion and the penetration
of microbes beyond the nasal submucosa are critical for the induc-
tion of innate and adaptive immune responses [2]. Given this, it
therefore would be valuable to generate a protective, long-lasting
immune response against pathogens at mucosal surfaces. Despite
this, challenges to effective mucosal vaccination include difficul-
ties in generating effective mucosal immunity, and the lack of safe,
effective mucosal adjuvants and delivery systems.
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The transport of antigens across the nasal epithelial barrier
is the first step in the induction of a mucosal immune response,
and antigen sampling in this process is influenced by a number
of factors. Entry of antigens or microbial pathogens into the mu-
cosal epithelium is dependent on molecular interactions between
the surface of the foreign material with host cell receptors that in-
clude complex glycoproteins, proteoglycans, and glycolipids [3,4].
Innate mucosal cells, such as macrophages, DCs, and respiratory
epithelial cells identify dangerous microorganisms through the
recognition of specific pathogen-associated molecular patterns in-
cluding Toll-like receptors (TLRs), NOD-like receptors, retinoic
acid inducible gene I-like helicases, and C-type lectins [5]. Translo-
cation of particulate antigens, intact bacteria, or viruses from the
upper airways to APCs, is believed to occur mainly in nonciliated
microfold cells (M-cells) [6,7] that are located in specialized tis-
sues such as the Waldeyer’s ring in humans and nasal-associated
lymphoid tissue (NALT) in rodents [8]. However, nonsoluble anti-
gen uptake can occur in sinonasal ciliated epithelial cells by in-
fection [9]. TLR-activated DCs (CD11c+ CX3CR1+ DCs) residing
in the baso-lateral side of gut mucosal tissues extend processes
across the tight junctions between epithelial cells and are also
capable of capturing pathogens [10]. It remains, however, un-
clear how this process occurs in the nasal mucosa although direct
luminal sampling by DCs is likely in areas of nasal stratified squa-
mous epithelia where no directional transcytosis is thought to
occur [11].
Several micro- and nano-polymeric vaccine delivery systems
have been developed and do not activate immune cells but protect
antigens from proteases in the mucosa. These materials appear to
enhance antigen uptake through transcytosis in nonciliated epithe-
lium or M-cells, but the induction of robust or protective immunity
with these materials often requires the addition of inflammatory
compounds [12].
Experimental mucosal adjuvants containing TLR agonists can
stimulate innate immune responses and promote protection
against pathogen challenge [13,14]. An adjuvant system utiliz-
ing TLR signaling approved for human use is included in Cervarix
(GlaxoSmithKline) that is a combination of alum and Monophos-
phoryl Lipid A (a TLR 4 ligand) [15]. In addition, enterotoxin-
based adjuvants, such as cholera toxin (CT) and Escherichia coli
heat-labile toxin (LT), which produce Th2-biased immune re-
sponses [16] to coadministered antigens have been shown to effect
antigen trafficking when administered intranasally [17]. However,
although CT and LT enhance antigen sampling, they also induce
inflammation though ADP-ribosyltransferase activity that perme-
abilizes the nasal epithelium, and this allows entry of vaccine
proteins into olfactory tissues. This limits clinical use because of
toxicity and potential brain and peripheral nerve inflammation
[18,19]. Thus, no nasal adjuvant has been fully effective and safe
for use in human vaccines and further development nasal ad-
juvants requires a better understanding of the mechanisms that
promote innate immunity [20,21].
The following studies were designed to evaluate the mech-
anism of adjuvant activity of a novel soybean oil-in-water
nanoemulsion (NE) nasal mucosal adjuvant. NE is unique in that
it induces immune responses in the absence of histological nasal
inflammation [22–25]. When mixed with protein antigens, NEs
promote robust mucosal immunity; high serum antibody titers;
and a cellular immune response consisting of Th1, Th2, and Th17
responses [22,23,26]. We found that NE immune induction in
ciliated epithelial-cells appears to mimic some aspects of respira-
tory viral infection in the nasal epithelium. It indicates that NE
nasal adjuvant induces unique immunomodulatory and antigen
trafficking activities that are different from toxin-based adjuvants
and demonstrate novel activities associated with immune poten-
tiation in the nasal mucosa.
Results
NE promotes mucosal antigen uptake and trafficking
to regional draining lymph nodes in vivo
To determine if the NE mucosal adjuvant is capable of enhanc-
ing antigen uptake, cytokine production, and DC trafficking to re-
gional lymph nodes, we first sought to evaluate NE’s capacity to en-
hance internalization of antigen after exposure in vivo. Quantum
dots (QDOTs, nondegradable nanometer-sized crystalline parti-
cles composed of cadmium selenide and surface modified to re-
duce nonspecific interaction) were used as surrogate antigen and
nasally administered in live outbred CD-1 mice in the presence
or absence of 20% NE. The distribution of QDOT-specific fluo-
rescence was imaged at 18 h (Fig. 1A). Significantly more flu-
orescence was observed at this time point in the nose, cervical,
and mediastinal LN regions following nasal administration of NE-
QDOTs as compared with that of QDOTs administered in PBS.
This suggested enhanced uptake of QDOTs in regional lymphatic
tissues after administration in NE.
To further characterize the distribution of protein antigens
after nasal administration in NE, 10 μg of GFP (used as a model,
protein antigen) was administered intranasally to CD-1 mice in
the presence of 20% NE. As shown in Fig. 1B, 18 h following
nasal exposure, more fluorescence was detected throughout the
nasal epithelium (a mixture of epithelium, connective tissues and
lymphocytes, cervical LN, and mediastinal LN in GFP-NE treated
mice than in mice exposed to GFP alone). GFP fluorescence was
broadly distributed through the epithelial barrier after nasal inoc-
ulation with NE. These data corroborated the QDOT whole body
distribution findings.
NE-mediated antigen uptake in the organized
nasal-associated lymphoid tissue
Nasopharyngeal M-cells are implicated in particulate antigen sam-
pling in nasal compartments in mice. We therefore qualitatively
evaluated NALTs (a mixture of epithelial cells, connective tissues,
and lymphocytes) [27] for the presence of GFP 18 h following
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Figure 1. NE promotes mucosal antigen uptake and trafficking to regional lymphoid tissue. (A) CD-1 mice were treated with QDOTs mixed with
NE, QDOTs in PBS, or 20% NE alone. In vivo fluorescence was measured at 18 h. The mouse furthest to the right in each group is a nontreated
control. Black bars: NE + QDOT, gray bars: QDOT only. *p < 0.05 Mann–Whitney test. Data are shown as mean of five mice per treatment and
experiments were performed twice with comparable results. (B) In situ fluorescent evaluation of the indicated cryo-preserved tissues in CD-1
mice 18 h following instillation of 7.5 μL/nostril of GFP (10 μg) either diluted in PBS or mixed with 20% NE. Magnification is 400×. Data shown
are representative of experiments performed on three mice per treatment, and repeated twice with comparable results. (C) In situ fluorescent
evaluation of the NALT in naı̈ve CD-1 mice or 18 h following instillation of 6 μL/nostril of GFP (10 μg) alone or in combination with 1 μg CT or 20%
NE. Tissues were evaluated with confocal microscopy; 400× magnification. Insets represent 800× magnification of the indicated boxed regions. The
dashed white line marked with an asterisk demarks the area of the subepithelial dome. Data shown are representative of experiments performed
on three mice per treatment and repeated twice with comparable results. (D) NALT cells (1–2 × 106/sample) isolated from CD-1 mice 36 h following
nasal treatment with 10 μg OVA-Alexa 647 ± 20% NE (10 μL/nostril) or 20% NE alone (10 μL/nostril) were analyzed for OVA-Alexa 647 uptake.
Numbers represent the percentage of cells that have internalized OVA-Alexa 647 among CD11c+ lymphocytes based on CD11c gating. Data shown
are representative of experiments performed on three mice per treatment, and repeated twice with comparable results. (See gaiting strategy in
Supporting Information Fig. 1). (E) Quantitative analysis of OVA+ DCs expressed in (D) as a percentage of total cells in NALTs + STD). *p = 0.0058,
Unpaired Student’s t-test.
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Figure 2. NE promotes in vivo sampling by ciliated
nasal epithelial cells without disruption of the ep-
ithelial barrier. TEM images of nasal epithelium from
CD-1 mice 18 h after nasal inoculation with QDOTs:
images of epithelium following 20% NE treatment
(7.5 μL/nostril) (A–E). The dashed line in (C) highlights
the tight junction between adjacent epithelial cells.
(D and E) Epithelium following intranasal inoculation
with QDOTs mixed with 20% NE. The dashed line in
(D) demarks the basal lamina. (E) Represents an ex-
pansion of the boxed area in (D). (F) An image of
control (nontreated) nasal epithelium. The magnifi-
cation of each section is listed above the photomi-
crograph in (A–F). Data shown are representative of
experiments performed on three mice per treatment
and repeated twice with comparable results. (G–H)
Intracellular BODIPY fluorescence (green) associated
with DQ-OVA uptake and processing in TC-1 epithe-
lial cells exposed to (G) DQ-OVA without adjuvant or
(H) a mixture of NE and DQ-OVA. The blue fluores-
cence represents DAPI nuclear stain. Data shown are
representative of two experiments performed with
comparable results. Magnification is 400×. (I) Flow cy-
tometry analysis of DQ-OVA uptake in primary nasal
septal epithelial cells. Single-cell suspension of pri-
mary nasal septal cells (1 × 106/sample) isolated from
C57bl/6 mice 2 h following nasal treatment with 4 μg
DQ-OVA ± 0.1% NE (orange histogram) or 4 μg DQ-OVA
alone (blue histogram). The red histogram indicates
the isotype control. Data shown are representative of
two experiments performed with comparable results.
(J) The percentage of cells containing processed DQ-
OVA is presented as mean ± SEM of three samples
per treatment and are representative of two experi-
ments. *Indicates statistical significance as analyzed
by unpaired Student’s t-test.
nasal administration (Fig. 1C) of either NE-GFP (bottom panel),
CT-GFP (third panel down), GFP only (second panel down), or
näıve mice (top panel). GFP was identified in the subepithelial
dome and along the luminal border in mice treated with GFP-NE
but not in mice treated with GFP in saline. Interestingly, GFP was
not detected in significant amounts in GFP-CT immunized mice at
that time point. The considerable presence of GFP in the NALT in
NE-GFP immunized mice suggests that NE also serves as a depot
promoting longer retention of the protein in the mucosa in com-
parison with CT. This was confirmed by flow cytometry, where
we observed a significant increase (p = 0.007) in OVA-Alexa 647
in CD11c+ NALT-isolated cells in NE-treated mice compared with
those from näıve mice (Fig. 1D and E and Supporting Information
Fig. 1).
NE-mediated transcellular antigen uptake in ciliated
epithelial cells
As indicated in Fig. 1B, NE-facilitated antigen uptake may not be
completely explained by APC sampling. Transmission electronic
microscopy (TEM) was employed to characterize the subcellular
distribution of NE-antigen in nasal mucosa 18 h after administra-
tion of QDOTs in NE in situ (Fig. 2A–F). We found that ciliated
cells (identified morphologically) contained vesicle-like material
homogenously distributed throughout the cytoplasm (Fig. 2A–C).
These vesicle-like structures appeared to be in endosomes [28] and
not apoptotic bodies [29] and had an average diameter of 0.479
microns consistent with the size of NE droplets. The QDOT-like
material present in the vesicle-like structure measured on average
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5 nm. Tight junctions in these cells remained intact despite the
lipid inclusions (Fig. 2C, dashed line) and, epithelial cells from
control mice had no cytoplasmic lipid structures (Fig. 2F). Un-
der higher magnification (Fig. 2D and E), QDOTS were detected
in vesicles and in the cytoplasm proximal to the basal lamina
(Fig. 2D, dashed line) indicating the material stayed with the NE
(Fig. 2E). NE-facilitated epithelial cell antigen uptake was con-
firmed in vitro using TC-1 cells (a murine respiratory epithelial
cell line) and in purified cultures of primary nasal septal epithe-
lial cells [30] collected from näıve adult C57BL/6N mice. Uptake
of antigen was analyzed by confocal microscopy in TC-1 and by
flow cytometry in primary nasal septal epithelial cells exposed
to a mixture of NE and ovalbumin labeled with fluorescent dye
BODIPY (DQ-OVA). Cells exposed to the mixture of NE and
DQ-OVA (Fig. 2H) had more intracellular BODIPY than did those
cells exposed to DQ-OVA alone (Fig 2G). Uptake was significantly
higher (p = 0.006) in primary epithelial cultures treated with NE +
DQ-OVA as compared with that of cells exposed to DQ-OVA with-
out NE (Fig. 2I and J).
NE mediates inflammation via calreticulin-associated
epithelial cell apoptosis and necrosis
We sought to determine the relevance of NE-facilitated antigen
uptake in ciliated epithelial cells for APC-associated antigen traf-
ficking. We hypothesized that NE-loaded epithelial cells undergo
apoptosis or necrosis, and are then sampled by DCs. To evaluate
this, nasal epithelium (a mixture of columnar epithelium, connec-
tive tissues, and lymphocytes) was harvested from mice 2 h follow-
ing exposure to 15 μL 20% NE or its components (cetylpyridinium
chloride (CPC) or NE without CPC (W805E)). The epithelium
was evaluated in situ for apoptosis by staining for caspase-3 and
by examining morphology for necrosis (Fig. 3A). Both caspase-3
expressing apoptotic (red arrows) and necrotic cells (black ar-
rows) were identified in NE-treated epithelium (Fig. 3A, lower
left panel), and these changes occurred without significant cellu-
lar inflammation. In contrast, tissues from mice treated with CPC
alone underwent severe necrotic changes (upper right panel) with
areas of complete epithelial disruption associated with neutrophil
infiltration (green arrows). Interestingly, mice treated with NE
without CPC (Fig. 3A, lower right panel) had similar architecture
in comparison with that of PBS-treated controls (Fig. 3A, upper
left panel), suggesting a role for CPC in the induction of apopto-
sis. Both the apoptotic and the necrotic processes associated with
NE were associated with limited, focal disruption of tight junctions
thus allowing para-cellular antigen infiltration into the epithelium.
To further characterize the apoptosis, nasal epithelial tissue sec-
tions were probed for calreticulin, an ectopically exposed protein
expressed by cells undergoing immunogenic cell death [31]. As
shown in Fig. 3B lower left panel, the epithelium from NE-treated
mice showed markedly positive staining for calreticulin that was
not observed in the epithelia from control animals (Fig. 3B, upper
left, upper right, and lower right panels). These results suggest
that NE uniquely induces immunogenic epithelial cell apoptosis
Figure 3. NE stimulates calreticulin-associated epithelial cell apopto-
sis and necrosis. (A) Nasal respiratory epithelium was harvested from
10-week old female C57BL/6N mice 2 h following treatment with 15 μL
20% NE or its components; CPC or NE without CPC (W805E). Dark brown
inclusions indicate caspase-3 staining (red arrows). Necrotic cells are
indicated by black arrows. Neutrophils are indicated with green arrows.
Magnification is 400×. (B) The nasal epithelium was probed for calretic-
ulin expression. Cells taking up stain for calreticulin appear dark brown
in color. Magnification is 200×. Data shown are representative of two
experiments performed, each with three mice per treatment, with com-
parable results.
that could stimulate APC activity and mediate the generation of
immunity.
NE stimulate accessory antigen presenting activity
of nasal epithelial cells
To analyze NE-induced local epithelial gene expression, whole
nasal mucosal tissue were harvested 6 and 24 h following nasal
instillation of 20% NE (15 μL) in healthy adult outbred CD-1 mice
as described in the Materials and methods (Complete microarray
data have been deposited in the public database Gene Expres-
sion Omnibus (GEO) under series accession number GSE25486).
Hierarchal cluster analysis of the expression of genes related
to antigen processing and presentation was performed on the
nasal mucosa using the GO term 0006955 Immune Response
(Fig. 4A). Upregulation of MHC class I and II transcripts and
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Figure 4. NE-modulated MHC class I and class II gene expression in
nasal mucosa. (A) Hierarchal cluster analysis of antigen processing and
presentation pathway gene expression in CD-1 mouse nasal mucosa
6 or 24 h following exposure to 20% NE (7.5 μL/nostril). Gene regulat-
ing expression of MHC class I or class II is indicated by the blue or
orange arrows, respectively. The colors represent significant (p < 0.05
and fold change >2 over control tissue) changes in gene expression
(Red: upregulated and green: downregulated). Gene expression data are
representative of two independent experiments each using three mice
per treatment. (B) MHC class II surface expression in primary nasal ep-
ithelial cells. A total of 1 × 106 nasal epithelial cells harvested from
C57BL/6N mice were treated with either 0.0001% NE, 10 μg CT, or media
alone for 12 h. The cells were probed for MHC class II expression and an-
alyzed via flow cytometry. MHC class II expression on primary epithelial
cells untreated (red histogram), NE-treated cells (blue histogram), and
CT-treated cells (orange histogram). MHC class II flow cytometry data
are representative of at least six independent experiments.
multiple other antigen presentation accessory molecules were ob-
served in the nasal mucosa at 6 and 24 h in NE exposed mice.
To determine if these NE activities enhance MHC class II ex-
pression in nasal epithelial cells, purified cultures of primary nasal
septal epithelial cells [30] were harvested from adult C57BL/6N
mice and probed for surface expression of MCH class II after treat-
ment with NE (0.0001%) and compared with treatment with cells
exposed to 10 μg/mL CT for 12 h or media alone as controls
(Fig. 4B). NE induced significantly more expression of MHC class
II in comparison with the control groups (p = 6.3 × 10−5) similar
to that which was observed with CT (p > 0.05).
DEC205+ DCs traffic NE-associated antigen to the
cervical LN
We also examined the phenotype of APCs associated with NE-GFP
in the superficial cervical LN, by examining colocalization of GFP
with DEC205, CD19, or CD11b using laser confocal microscopy.
Eighteen hours following the administration of 10 μg GFP ± 20%
NE (15 μL), GFP was observed to localize in DEC205+ cells but not
in CD19 or CD11b expressing cells in the cervical LN (Fig. 5 and
Figure 5. NE adjuvant promotes in vivo GFP localization in cells ex-
pressing DEC205. Colocalization of GFP (green) and DEC205 surface
markers (red) in the cervical LNs of CD-1 mice 18 h after nasal treat-
ment with 13 μg GFP plus 20% NE (15 μL). The photomicrograph in the
upper left corner represents GFP. The photomicrograph in the upper
right corner represents red channel fluorescence (DEC205). The pho-
tomicrograph in the lower left corner represents ultraviolet channel
fluorescence (DAPI). The photomicrograph in the lower right corner
represents the overlay image of all of the channels. Scale bar: 10 μm.
Data shown are representative of two experiments performed, with
comparable results.
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data not shown). These results indicate that mature DCs efficiently
traffic NE-associated antigen to regional LN following nasal NE-
antigen administration.
Innate and adaptive immune responses after NE or CT
stimulation in vivo
To define NE-specific effects on the innate cytokine profile of
nasal tissue, RNA from isolated nasal mucosa (a mixture of ep-
ithelial cells, connective tissues, and lymphocytes) was harvested
following administration of 20% NE (15 μL) in healthy adult
CD-1 mice. Microarray analysis showed 2968 (1975 upregulated
and 993 downregulated) changes in gene expression at 6 h versus
animals receiving PBS (complete microarray data have been de-
posited in the Gene Expression Omnibus (GEO) data base under
series accession number GSE25486). These data were analyzed
for immune-related genes (KEGG term cytokine–cytokine interac-
tion (04060)), and expression of only 22 genes (10.5%) showed
significant increases at 6 h after nasal treatment with NE. RNA
transcripts from the pro-inflammatory cytokines/chemokines GM-
CSF, IL-1b, IL-6, KC, MCP-1, MIP-1α, RANTES, TNF, CXCL9,
CXCL13 CXCL2, and CCL12 were significantly increased after ex-
posure to NE.
Changes in protein concentration in homogenized nasal septal
tissue collected from C57BL/6 mice treated with either NE or CT
(and compared with that of PBS administration) were evaluated
using a Luminex mouse 22-plex cytokine/chemokine kit and stan-
dard ELISA (Fig. 6A and C). Nasal treatment with 15 μL of 20%
NE was associated with increases in the cytokines G-CSF, IL-1a,
IL-5, IL-6, IL-12, IP-10, TGF-β, KC, and the DC maturation cytokine
TSLP by 18 h. In contrast, the cytokine response profile of 1 μg
of CT significantly differed from NE, with increases only in IL-6
and IL-12. The broader cytokine profile associated with the NE
adjuvant includes both IL-6 and TGF-β, which relate to adaptive
Th17 responses [26,32].
While most studies evaluating adjuvant activity have focused
on professional APCs we compared the cytokine profiles induced
by NE in both epithelial cells and APCs given the ciliated epithelial
cell data presented above (Fig. 2). This was done by stimulating
bone marrow derived DCs (BMDCs) harvested from C57BL/6 mice
with a range of either NE concentrations (0.001 to 0.1%) or CT
(1 μg, 10 μg, or 30 μg). The cells were collected and evaluated
for the presence of cytokines and chemokines using the Luminex
assay described above (Fig. 6B and C). As compared with control
cells, NE was found to stimulate significant production of four cy-
tokines in supernatants from these cells including GM-CSF, IL-1α,
IL-1β, and MIP-1α. CT also stimulated IL-1a, IL-1b, and MIP-1a in
BMDCs in addition to 13 others including IP-10, G-CSF, IL-10, IL-4,
IL-6, IL-9, IL-12, IL-15, IL-17, TNF-α, and KC; therefore the profiles
were very different. Interestingly, the only NE-stimulated cytokine
significantly increased in both the nasal septum and BMDCs was
IL-1α.
To validate these results, TC-1 epithelial cells were incubated
in media with either NE or CT as above. The supernatant from
treated cells were evaluated with ELISA for IL-6, TGF-β, and TSLP
(Fig. 6A and C). Significant amounts of IL-6, TGF-β, and TSLP were
measured in supernatant collected from cells incubated with NE;
however, only IL-6 was induced in response to CT. Collectively,
this data indicate that NE uniquely promotes innate cytokine and
chemokine activity in epithelial cells in addition to activating APCs.
Evaluation of the role of the IL-6 cytokine in the
adjuvant activity of NE
IL-6 is significantly produced in the nasal mucosa after exposure
to NE, but the exact role of IL-6 in the acute phase response
in the nasal mucosa is poorly understood [33]. To characterize
its role NE-induced immunity, we immunized mice deficient in
the ability to produce IL-6 (IL-6-/-) with 20% NE + 20 μg rPA
and compared rPA-specific splenocyte responses from IL6-/- and
WT mice (Table 1). IL-5 cytokine secretion trended higher in the
IL-6-/- mice while IFN-γ, TNF-α, and IL-17 trended lower. Thus,
these results suggest that IL-6 plays an important cytokine in NE-
mediated immune activation in the nasal respiratory mucosae.
Discussion
Previous studies have documented that intranasal immunization
with high-energy NEs and either whole organism or recombi-
nant proteins induces a broad and unique immune response
[23,26,34,35]. However, the mechanisms of NE adjuvant activ-
ity are still unknown and this hinders the development of these
adjuvants. In addition, enhancing the knowledge into the mech-
anisms of action of other mucosal adjuvants, including CT, also
will aid in the rationale design of improved adjuvant formulations.
The present study examines novel NE adjuvant activities involv-
ing uptake of antigen and immunoregulatory cytokine production
by ciliated nasal epithelial cells in the absence of inflammation
in comparison with CT. We also examined the effects of NE on
antigen internalization in nasal mucosa, its uptake by APCs and
subsequent trafficking to draining lymph nodes. Several unique
activities were observed.
Our current studies document that NE not only enhanced anti-
gen uptake in the NALT but also, for the first time, we demonstrate
enhanced uptake in ciliated epithelial cells using a mucosal adju-
vant (Fig. 1). The presence of emulsion droplets containing QDOTs
in ciliated epithelial cells (Fig. 1D and E) suggests that the cells in-
ternalize this material through a process that does not disrupt tight
junctions or cell membranes. These results also suggest that nasal
mucosa NE antigen uptake does not require M-cell or DC luminal
sampling. This unique route of facilitated antigen uptake in nasal
tissues appears to be transcellular as opposed to para-cellular as
evidenced by the finding that tight-junctions remain intact despite
the presence of NE (Fig. 1C). Furthermore, no disruptive changes
or inflammation were observed in the epithelial layer on either
the EM images or with light microscopy [23]. Together, these
data suggest that NE is able to induce unique systemic immune
responses through a new pathway for antigen uptake leading to
DC migration from mucosa to systemic lymphatic tissues.
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Figure 6. NE has unique immunomodulatory function in respiratory mucosa. (A) Immunodetection of NE-driven, mucosally secreted innate
cytokines and chemokines after intranasal treatment with NE. Cytokine and chemokine secretion in homogenized nasal septal tissues collected
from C57BL/6N mice 18 h following intranasal administration of 20% NE (7.5 μL/nostril), or 1 μg CT (7.5 μL/nostril), or PBS (7.5 μL/nostril). Protein
detection is expressed in group average protein concentration in pg/ml + SEM of three mice per treatment and data are representative from two
experiments. (B) Immunodetection of cytokines and chemokines in BMDCs. A total of 4 × 106 BMDCs (n = 3 cultures/treatment) were stimulated
with 0.001%, or 0.01% or 0.1% of NE, or 1 μg/mL, or 10 μg/mL or 30 μg/mL of CT for 24 h. Protein detection is expressed in group average protein
concentration in pg/mL + SEM. This assay was repeated twice for verification. The data are representative of 1 of the 2 experiments performed
with comparable results. (C) VENN diagram comparing the NE-specific versus CT-specific profiles of cytokines and chemokines in nasal mucosa
versus BMDCs. *Validated NE-specific production in TC-1 epithelial cells. Data were analyzed by unpaired Student’s t-test.
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Table 1. Cytokines produced by splenocytes from IL-6-/- or WT mice
with NE + rPA following stimulation with rPA in vitro




IFN-γ 1 (0.1) 37.09 (3.71± 3.13)
TNF-α 1 (0.1) 142.9 (14.29 ± 7.43)
IL-2 8.75 (67.3 ± 47.53) 2.97 (37.39 ± 14.28)
Th2 type
IL-6 1.09 (5.58 ± 0.85) 2.38 (30.2 ±10.9)
IL-4 78.5 (7.85 ± 6.71) 9.36 (7.84 ± 3.37)
IL-5 308.57 (175.89 ± 146.39) 14.19 (51.28 ± 26.02)
IL-10 2.86 (21.03 ± 12.22) 1.52 (50.17 ± 15.32)
Th17 type
IL-17 39.14 (3.91 ± 3.3) 2.88 (58.61 ± 25.39)
a)Shown are the averages of ratio (stimulation plus rPA/stimulation
with media without rPA) for four different mice. The numbers in
parenthesis represent absolute values in pg/mL ± SEM. Cytokines
were detected by Luminex assay as explained in the section Mate-
rials and methods.
The ability of NE to promote transcellular antigen uptake may
be related to “lipidizing” proteins to enhance transcellular ab-
sorption in respiratory epithelial barriers. Mixing antigen with NE
appears to trap the antigen in the oil phase [23] allowing tran-
scellular migration across the apical membrane, through the cell
cytoplasm, and across the basolateral membrane. This is the main
route of permeation for hydrophobic compounds across the mu-
cosa and is very efficient given the surface area of the transcellular
approach is much larger by a factor of 9999 to 1 than the surface
area of the para-cellular route (tight junctions) [36,37]. Also, the
finding that lipid droplets penetrating the nasal mucosa induce
Th1, Th2, and Th17 type of immune response may suggest that
this system evolved to deal with lipid-covered respiratory viruses,
especially since the emulsion droplets are approximately the same
size as viruses, are highly surface active, and readily endocytosed
by epithelial cells.
Following epithelium cell uploading of the NE-antigen com-
plex, DEC205+ cells appear to locally sample antigen in the epithe-
lia and then migrate to the systemic lymphatic circulation (Fig. 5).
Optimal conditions and regulations of initial antigen sampling and
activation of DCs causing migration to draining lymph nodes is
not very well understood at this moment. We found that some NE
and antigen-loaded epithelial cells undergo calreticulin-associated
apoptosis and necrosis (Fig. 3). DCs most likely take these antigen-
loaded dead cells up. We hypothesize that host DNA released from
dying cells may act as a damage-associated molecular pattern that
mediates DC activation, potentially in a similar fashion as has been
reported for alum [38]. It is also possible that there is direct in-
teraction between NE and antigen-loaded ciliated epithelial cells
and antigen-specific CD4+ and CD8+ cells in sinonasal epithelium.
This hypothesis seems plausible given the fact that NE stimulates
accessory antigen processing and presentation activities by MHC
class I and II in epithelial cells (Fig. 4). Finally, the possibility
that epithelial cells secrete biologically active exosomes capable
of uptake by DCs or presenting antigenic peptide in the context of
MHC class I or class II to näıve T cells merits further investigation
[39,40]. Any of these processes could activate DCs and account
for lymphatic migration.
Nochi and colleagues have demonstrated that nanogel, when
applied intranasally, activates cytokine production and generates
cellular immune responses [41]. The majority of mucosal adju-
vants cause local inflammation that attracts and activates antigen-
presenting cells through cytokines, chemokines, and multiple sig-
naling pathways such as MyD88 [42,43]. This microenvironment
facilitates local antigen sampling by DCs and enhances presenta-
tion to the immune system after toxin administration. However,
our findings suggest that the mechanisms of NE adjuvant activi-
ties appear to be distinctive from that of CT (Fig. 6) and possibly
other nasal adjuvants. This is supported by the unique and hetero-
geneous production of cytokines and the absence of histological
inflammation [23].
In these studies, we demonstrated that NE induces a cytokine
profile that supports antigen-specific adaptive Th17 responses. In
the intestinal mucosa, Th17 cells are the main source of IL-17,
whereas in the respiratory mucosa γδT cells, NKT, NK, RORγt, and
NKp46+ cells are the main producers of IL-17. Effector antibac-
terial and antifungi functions of IL-17 are attributed to the in-
teraction with IL-17R expressed on fibroblasts and epithelial cells
to induce MCP-2, G-CSF, and CXC chemokines. IL-22 is another
important cytokine produced by Th17 for inducing the secretion
of antimicrobial peptides and β-defensin-2 by epithelial cells and
for contributing to barrier function and tissue repair [44]. Beyond
its role in the Th17 pathway, IL-6 also enhances innate immunity
and antibody production following mucosal vaccination [45,46].
IL-6 may actually be muco-protective, downregulating TNF and
IL-1 [47,48] and has been shown to enhance transcellular passage
of microbes through the epithelial barrier. The exact mechanism
of epithelial cell production of IL-6 in response to NE exposure
requires further investigation.
In the future, the development of mucosal vaccines against in-
fectious diseases will necessitate the development of safe and ef-
fective mucosal adjuvants and delivery systems. In these studies,
we demonstrate NE-mediated antigen uptake into ciliated epithe-
lium that facilitates DC antigen loading and migration to mucosal
and systemic lymphatic tissues. NE also uniquely enhanced het-
erogeneous cytokine and chemokine production by epithelial cells.
These responses may have a significant role in inducing protection





and C57BL/6N mice were purchased from Charles River
Laboratories (Wilmington, MA). IL-6 gene deficient mice (IL-6–/–)
C© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
2082 Paul E. Makidon et al. Eur. J. Immunol. 2012. 42: 2073–2086
(B6.129S6-IL6TM1KOPF) and C57BL/6J mice were purchased from
Jackson Laboratories. All mice were housed in specific pathogen-
free conditions in facilities maintained by the University of Michi-
gan Unit for Laboratory Animal Medicine. The University Com-
mittee on Use and Care of Animals (UCUCA) at the University of
Michigan approved all procedures performed on mice. In regards
to characterization of humoral and cellular immune responses to
NE-based vaccines, there have been no significant differences in
response between strains, and the results observed in CD-1 mice
also seen in C57BL/6 mice in previous studies.
Cell culture
Primary nasal epithelial cells were cultured from the nasal sep-
tum of C57BL/6N mice as previously described [30] with minimal
exceptions. Purity was verified by probing for the lack of MHCII,
CD11c, and CD11b. Mouse BMDCs were generated and main-
tained as described previously [49].
The murine pulmonary epithelial cell line TC-1 was obtained
from ATCC (CRL-2785TM) and cultured in RPMI 1640 containing
L-glutamine (2 mM) supplemented with 10 mM HEPES, 1 mM
sodium pyruvate, 100 μM MEM NEAA, 10% heat-inactivated FBS,
100 μ/ml Penicillin, and 100 μg/mL Streptomycin.
Nanoemulsions (NEs)
NEs were provided by NanoBio Corporation and obtained by
nanoemulsification of Tween 80, CPC, ethanol as a solvent, highly
purified soybean oil, and water.
Antigens
Enhanced GFP was acquired from BioVision Research Products.
Alexa Fluor 647-conjugated OVA protein (OVA-Alexa 647) were
purchased from InvitrogenTM. Recombinant rPA from Bacillus an-
thracis were purchased from List Biological Laboratories, Inc.
QDOTs (Qtracker 655 non-targeted) were purchased from Quan-
tum Dot Corporation.
QDOT assay in vivo
QDOTs were used as a model antigen due to their high level of in
vivo fluorescence and their ability to interact with the lymphoid
tissues in the mice [50]. Groups of four mice were inoculated in-
tranasally with 15 μL of QDOTs (6.6 μL of 2 μM solution, ±20%
NE). In-life fluorescence analysis was performed in isoflurane-
anesthetized mice using the IVIS Imaging System 200 Spectrum
series bioluminometer (Xenogen). The fluorescent measurement
was quantified using IVIS Living Image 3.1 software. Mouse no.
2 in the NE only treatment group died under anesthesia during
the 4-h imaging time point. QDOT-specific fluorescent intensity is
represented on an increasing scale from blue (1. × 107), green (5
× 107), yellow, (7.5 × 107), and red (1 × 108) photons/s/cm2/sr.
The fluorescent measurement was quantified in the indicated re-
gions and normalized to the signal collected from the blank on
each mouse.
Antigen localization
To determine the localization of GFP antigen in different tissues
18 h after nasal vaccination, the mice were nasally immunized
(15 μL/mouse) with a mixture of GFP (10 μg/mouse) ± NE
(20%). The animals were sacrificed 18 h following inoculation,
and nasal epithelium (a mixture of ciliated and nonciliated colum-
nar epithelium, connective tissues, and APCs), superficial cervical
lymph nodes, mediastinal lymph nodes, and organized NALTs [27]
were collected in OTC (TissueTek) and frozen by slow immersion
in liquid nitrogen. Tissue sections were cut in 5 μm sections and
placed on glass slides for evaluation using light microscopy. NALTs
were imaged with a Zeiss LSM501 laser confocal microscopy.
FACS analysis
Immunofluorescent studies of NALTs were confirmed using FACS.
The presence of OVA-Alexa 647 was analyzed in single cell
suspensions derived from NALTs of CD-1 mice 36 h follow-
ing nasal immunization with 10 μg OVA-Alexa 647 ± 20% NE
(15 μL/mouse). The cells were stained with APC hamster anti-
mouse cD11c (BD PharmingenTM), rat anti-mouse cD19: Pacific
Blue R© (AbD serotec), PE anti-mouse cD11b (BioLegend), or their
respective isotype. Samples were acquired using a LSR II (BD Bio-
sciences). Data were analyzed on DIVA software (BD Biosciences).
For these studies, we utilized the following gating strategy. Alex-
afluor 647+ cells were identified in populations of CD11c+ or
CD11b+ live cells based on side scatter versus CD11c or CD11b
analysis.
FACS analysis of NE-inducible MHC class II
expression in primary nasal epithelial cells
A primary culture of nasal septal epithelial cells was prepared as
above. A total of 1 × 106 cells were incubated with 0.001 or 0.01
or 0.1 NE. Positive controls included 100 ng-500 ng LPS (E. coli
K12) or 400 units of recombinant mouse TNF-a (Invitrogen). Neg-
ative controls included no treatment (media alone). The treated
cells were washed, suspended in FACS buffer (Biolegend), and
blocked on ice with TruStain fcX, Biolegend). The cells were then
stained with 0.25 μg/106 cells of anti-I-A/I-E-alexa flour 647 (Bi-
olegend) or isotype control for 20 min on ice. The cells were then
washed twice and resuspended in FACS buffer prior to analysis via
flow cytometer using a BD Accuri C6 Flow cytometer utilizing the
following gating strategy. Based on analysis in a side and forward
scatter plot, the dominant population (>95%) was analyzed for
marker-specific signals.
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Phenotype identification of NE-mediated APCs
trafficking to draining lymph nodes
Superficial and deep cervical lymph nodes were harvested di-
rectly postmortem from CD-1 mice 18 h following treatment with
GFP plus 20% NE (15 μL). The tissue was fixed in 10% buffered
formalin and paraffinized. The tissue sections were blocked for 10
min using the Power Block
R©
solution (BioGenex), and stained with
anti-GFP fluorescent antibodies or control same isotype antibodies
in PBS containing 0.1% BSA overnight at 4◦C. Tissue was stained
with the DC markers DEC205 (Rabbit anti-mouse CD205 mAb
[Serotech]) and CD11c (rabbit anti-mouse cD11b [Abcam]) or
macrophage marker cD11b. GFP was detected with mAb anti-GFP
(rabbit pAb anti-GFP [Biosystems]). Goat anti-rabbit DylightTM
594 (Biocare Medical) was used as a secondary antibody to rabbit
primaries. The stained tissue samples were mounted in ProLong
(DAPI blue nuclear stain Molecular Probes
R©
). Imaging was per-
formed using a Zeiss LSM501 laser confocal microscopy.
Electron microscopy of nasal epithelium
The sinus cavities were excised 18 h postinoculation and immer-
sion fixed in 2.5% glutaraldehyde in 0.05 M cacodylate buffer,
pH 7.4, at room temperature for 4 h. After fixation, the sections
were demineralized in 7.5% disodium EDTA with 2.5% glutaralde-
hyde for 7 days following a protocol adapted from Shapiro et al.
[51]. Ultra-thin sections were viewed without poststaining on a
Philips CM100 at 60 kv. The images were recorded digitally using
a Hamamatsu ORCA-HR digital camera system.
Antigen uptake and processing in epithelial cells
in vitro
For uptake analysis in an epithelial cell line, 1 × 105 TC-1 cells
were seeded in RPMI 1640 media (with L-glutamine; Mediatech,
Inc.) with 10% heat-inactivated fetal bovine serum, 1% nonessen-
tial amino acids, 10 mM HEPES, 1 mM sodium pyruvate, 1% peni-
cillin/streptomycin overnight at 37◦C on Lab-tek chambered cov-
erglass slides (Nunc). A mixture of DQTM ovalbumin (DQ-OVA;
Life Technologies) with 1:6 NE, or DQ-OVA alone was prepared in
Dulbecco’s PBS (DPBS; Life Technologies) at 10 times the desired
final concentration, and added to the media in the cell cham-
bers to achieve a final concentration of 0.012% NE and 2 mg/mL
DQ-OVA. Samples were incubated for 1 h at 37◦C. Media was re-
moved, and cells were washed three times with DPBS, and fixed in
4% paraformaldehyde in DPBS for 10 min at room temperature.
Slides were mounted in Prolong Gold Antifade with DAPI. Cells
were imaged on a Zeiss LSM 510-META laser scanning confocal
microscopy system.
For uptake analysis in primary epithelium, nasal epithelial cells
were cultured from the nasal septum of C57BL/6N mice as pre-
viously described [30]. The following treatments were applied in
duplicate at 300 μL per well, DQ-OVA only at 4 μg/mL in PBS,
0.05% NE with 4 μg/mL DQ-OVA in PBS, and a PBS only control.
These were incubated at 37◦C with 5% CO2 for 2 h. Pelleted cells
were resuspended and flow cytometry was performed using an Ac-
curi C6. A total of 20,000 events were collected for each sample.
The gating strategy was based on analysis in a side and forward
scatter plot. In this plot, the dominant population (>95%) was
analyzed for BODIPY-specific signal.
Detection of apoptosis and necrosis
To evaluate the induction of NE-driven apoptosis of nasal epithe-
lium (a mixture of epithelial cells, connective tissues, and lym-
phocytes), C57BL6/N mice were nasally treated with 20% NE
(15 μL). To determine if the NE mixture itself or its components
do so, other mice were treated with either the equivalent concen-
tration of CPC contained in 15 μL of 20% NE, with 20% W805E (a
nonionic NE), or with sterile PBS. Nasal septal epithelium was har-
vested [30] and fixed in 10% buffered formalin for 24 h. Antigen
retrieval was performed in DIVA decloacker buffer and blocked
with peroxidase and Rodent block M (Biocare Medical) for 5 and
30 min, respectively according to manufacturer’s recommenda-
tions. Tissues were stained with a 1:1000 dilution of pAb rab-
bit anti-Caspase-3 pAb (Cell Signaling) or with a 1:3000 dilution
of rabbit pAb anticalreticulin (Abcam) for 1 h. Following wash,
Rabbit-on-Rodent HRP-Polymer was applied for 30 min according
to manufacturer guidelines. DAB chromogen was applied and the
side was counterstained with Cat hematoxylin (Biocare medical).
Identification of cells dying by necrosis was characterized mor-
phologically according to defined criteria [52]. In brief, necrotic
cells were identified as cells containing dilated organelles and dis-
sociated ribosomes from the endoplasmic reticulum. These cells do
not contain pyknotic or fragmented nuclei and the degeneration
proceeds without any detectable involvement of lysosomes. These
experiments were performed twice with comparable results.
Epithelial gene expression analysis using microarrays
To evaluate regulation of NE-mediated changes in gene expression
in nasal epithelial tissues, nasal septal epithelium was harvested
immediately postmortem from CD-1 mice at either 6 h or 24 h
following nasal treatment with either 20% NE (15 μL) or ster-
ile PBS (15 μL). The tissue was collected in OTC and frozen by
slow immersion in liquid nitrogen and stored at –80◦C until used
for microarray analysis. Total RNA was extracted per sample us-
ing RNeasy (Qiagen) according to the manufacturer’s instructions.
RNA samples were pooled and processed using an Ovation Biotin
Labeling system from NuGen, Inc. following manufacturer’s proto-
cols. Prior to hybridization, the quality of RNA was accessed using
an Agilent 2100 Bioanalyzer. Hybridization, detection, and scan-
ning was performed using a mouse GeneChip
R©
430 2.0 manufac-
tured by Affymetrix and a Affymetrix Scanner 3000 following man-
ufactures guidelines. Gene expression values were calculated us-
ing a robust multiarray average (RMA) [53]. Complete microarray
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data have been deposited in the public database Gene Expres-
sion Omnibus (GEO) under series accession number GSE25486
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi). This assay
was replicated for accuracy.
Analysis of cytokine and chemokine expression in
BMDCs or in nasal septal tissues
BMDCs were cultured for 5 days as described above. A total of 4 ×
106 BMDCs/treatment were stimulated with 0.001, 0.01, or 0.1%
NE, 1, 10, or 30 μg/ml CT (List Laboratories). As a positive con-
trol BMDCs were treated also with 1 or 10 ng/ml LPS Salmonella
minnesota (List Laboratories) or left untreated as negative con-
trol. The cells were stimulated in 2 mL/well of the medium with
lowered content of FBS (2%) and mGM-CSF (1.5 ng/mL) at 37◦C
5% CO2 atmosphere for 24 h. Cytokine secretion was measured in
supernatant using bead-based multiplex assay according to man-
ufacturer protocol as described above (Millipore Multiplex 22).
Mucosal cytokines/chemokines were also analyzed in vivo.
C57BL6/N mice (n = 3) were intranasally treated with 15 μL
of 20% NE, 1 μg CT, or sterile PBS. Nasal septal epithelium was
collected as above directly postmortem 18 h following treatment.
The epithelium was manually homogenized using mortar and pes-
tle and then gently digested using T-PER tissue extraction reagent
(Thermo Scientific) according to manufacturer’s recommendation.
Cytokine secretion was measured in supernatant using bead-based
multiplex assay according to manufacturer protocol as described
above (Millipore Multiplex 22). Additionally, the supernatant was
evaluated for the presence of TGF-β 1 and thymic stromal lym-
phopoietin (TLSP) via ELISA using a mouse/rat/porcine/canine
TGF-ß1 immunoassay kit (Quantikine) and Mouse TSLP Im-
munoassay kit (Quantikine
R©
) according to manufacturer’s recom-
mendations.
To evaluate the potential for NE to mediate cytokine expression
in epithelial cells, 4 × 106 TC-1 cells were incubated with 0.001,
0.01, or 0.1% NE. The supernatant was evaluated using ELISA for
TGF-β1, and TSLP as above. IL-6 was also measured using a custom
ELISA. In brief, 96-well MaxiSorp
R©
(Nunc) plates were coated
with 2 μg/mL rabbit pAB anti-IL-6 (Abcam) and blocked with
peroxidase. After washing, 100 μL of nondiluted supernatant/well
was incubated on the plate for 2 h. After washing, 50 μL of a 1:200
dilution biotinylated anti-IL6 antibody (Abcam) was incubated in
each well for 2 h. After washing, the plate was developed with
streptavidin-HRP and read at an absorbance of 450 nm.
Immunization protocol for IL-6 mechanistic studies
For studies evaluating the role of IL-6, groups of IL-6−/– and WT
(C57BL/6J) mice (n = 5) were i. n. immunized with 20 μg rPA ±
20% NE (12 μL), or sterile PBS (negative controls) on days 0 and
28. At week 6, the animals were euthanized and the spleens were
immediately harvested and processed into a single cell suspension.
rPA-specific in vitro recall responses were analyzed as previously
described [24].
Statistical analysis
Statistical comparisons were assessed by two-way ANOVA with
Tukey comparison, Student’s t-test, and Mann-Whitney test by us-
ing GraphPad Prism version 5.00 (GraphPad Software, San Diego
CA; www.graphpad.com). A p value < 0.05 was considered sig-
nificant.
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